http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-100542534-C
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d9880469dc8f12dad7c3ad95c6ab31fe |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-496 |
| filingDate | 2004-12-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2009-09-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_05f911efd0507592d3d95140d946398a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3b2f1fabe249f2f814db2fe3d59b98a5 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a85339e9f29d7e3fe57c5aa490d85b60 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_76926ac954db94f1d8aaba33046de4e2 |
| publicationDate | 2009-09-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-100542534-C |
| titleOfInvention | The piperazine that replaces |
| abstract | Chemical compound as the strong antagonist of CCR1 receptor is provided, and this chemical compound has intravital anti-inflammatory activity.This chemical compound is aryl piperazine derivative and can be used for pharmaceutical composition normally, is used for the treatment of the method for the disease of CCR1-mediation, and in the test of identifying competitive CCR1 antagonist in contrast. |
| priorityDate | 2003-12-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 1101.